Financial Assistance Program for All Qualifying Patients

JETREA CARE® can investigate if your patient qualifies for one of these 3 programs to help with their out-of-pocket financial responsibility.

JETREA® CO-PAY
ASSISTANCE PROGRAM
For patients insured through commercial insurance plans* Covers JETREA® out-of-pocket costs in excess of $25, including co-pay or co-insurance, and/or deductible
Referral to independent nonprofit co-pay foundations For patients insured through government sponsored programs
(ie, Medicare, Medicaid, TRICARE, VA, and Federal Employee Health
Benefits Program)
Offers co-pay assistance
for patients
JETREA CARE® Patient Assistance Program For uninsured patients§ Provides JETREA at no cost
 
Enroll your patients in JETREA CARE® to determine eligibility for patient assistance consideration
*Eligibility is based on limited income requirements, with the annual household adjusted gross income of up to $150,000.
JETREA CARE® CO-PAY ASSISTANCE PROGRAM does not apply to patient financial responsibility for the injection procedure. Co-pay assistance is capped at $2,000. Patients with any remaining balance will be referred to a nonprofit foundation.
Independent nonprofit foundations provide assistance regardless of the choice of medicine, and decisions are based on financial need and according to criteria established by individual foundations. JETREA CARE® can assist patients by referring them to these independent nonprofit foundations. Neither ThromboGenics® nor JETREA CARE® can guarantee that patients will be eligible for or receive co-pay assistance after referral. Neither ThromboGenics® nor JETREA CARE® have controlling or managerial influence on these independent nonprofit foundations.
§Eligibility is based on limited income requirements, with the annual household adjusted gross income of up to $100,000.
JETREA CARE® Patient Assistance Program does not apply to patient financial responsibility for the injection procedure, only the drug is provided at no cost.

Indication

JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.

Important Safety Information

Warnings and Precautions

  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).

Adverse Reactions

  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

Please see full Prescribing Information for JETREA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Health Care Professional.